| Catalog No. | HV698016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
FcRL5, FCRH5, FCRL5, Fc receptor homolog 5, FcRH5, CD307e, FcR-like protein 5, IRTA2, Immune receptor translocation-associated protein 2, BXMAS1, Fc receptor-like protein 5, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q96RD9 & P07766 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | Bispecific, BFCR-4350-A, BFCR-4350A, RG-6160, RO-7187797, 2249888-53-5 |
|---|
| Background | Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
